Floatz logo

Therapeutic Asset Ratings

6,302 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Repotrectinib
Central Nervous System Neoplasm
Turning Point Therapeutics, Inc.P1/2CC (46)
Ribociclib
Endometrial Carcinoma
Avenzo Therapeutics, Inc.P1/2CC (46)
Ribociclib
Fallopian Tube Cancer
Avenzo Therapeutics, Inc.P1/2CC (46)
Ribociclib
Ovarian Serous Adenocarcinoma
AstraZenecaP1/2CC (46)
Ribociclib
Triple-Negative Breast Carcinoma
Avenzo Therapeutics, Inc.P1/2CC (46)
Rimiducid
Aplastic Anemia
Bellicum PharmaceuticalsP1/2CC (46)
Rimiducid
Hemoglobinopathy
Bellicum PharmaceuticalsP1/2CC (46)
Rimiducid
Childhood Acute Myeloid Leukemia
Bellicum PharmaceuticalsP1/2CC (46)
Rimiducid
Osteopetrosis
Bellicum PharmaceuticalsP1/2CC (46)
Ris-Rez
Neoplasm
GlaxoSmithKlineP1/2CC (46)
Rmc-9805
Non-Small Cell Lung Carcinoma
Tango Therapeutics, Inc.P1/2CC (46)
Ruxolitinib
Prostate Adenocarcinoma
University of Michigan Rogel Cancer CenterP1/2CC (46)
Samuraciclib
Estrogen-Receptor Positive Breast Cancer
Hoffmann-La RocheP1/2CC (46)
Samuraciclib
Malignant Pancreatic Neoplasm
University Health Network, TorontoP1/2CC (46)
Sarilumab
Endometrial Cancer
Regeneron PharmaceuticalsP1/2CC (46)
Saruparib
Biliary Tract Cancer
AstraZenecaP1/2CC (46)
Selpercatinib
Infantile Myofibromatosis
Eli Lilly and CompanyP1/2CC (46)
Seviteronel
Triple-Negative Breast Carcinoma
St Vincent's Hospital, SydneyP1/2CC (46)
Sonrotoclax
Myelodysplastic Syndrome
BeiGeneP1/2CC (46)
Spironolactone
Glioblastoma
Starlight Therapeutics Inc.P1/2CC (46)
Sulfasalazine
Glioblastoma
University of ZurichP1/2CC (46)
Surufatinib
Rhabdomyosarcoma
HutchmedP1/2CC (46)
SX682
Oropharynx Squamous Cell Carcinoma
National Cancer Institute (NCI)P1/2CC (46)
Talazoparib
Hepatoblastoma
St. Jude Children's Research HospitalP1/2CC (46)
Talazoparib
Osteosarcoma
St. Jude Children's Research HospitalP1/2CC (46)
Showing 3276 to 3300 of 6,302 assets
PreviousPage 132 of 253Next